Photo of Thomas Keck

View Scopus Profile

Thomas Keck

  • 425 Citations
  • 14 h-Index
20062020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Research Expertise:
Pharmacology | Neuroscience | Biochemistry

I am interested in developing new medications for neuropsychiatric disorders, including Alzheimer’s disease, schizophrenia, ADHD, pain, anxiety, and a particular interest in drug addiction. My lab works closely with medicinal chemists to design and test new drug-like molecules, combining molecular and behavioral pharmacology methods to evaluate the preclinical potential of new compounds designed to target the dopamine D4 receptor, the µ opioid receptor, and the trace amine-associated receptor 1, among others.

Honors and Awards:
2017 Maharaj Ticku Memorial Travel Fellowship for New Investigators Award, Behavior, Biology and Chemistry Conf.
2015 Frances R. Lax Faculty Development Award, Rowan University
2013 Mentoring Award for Fellows, NIDA-IRP, NIH
2013 Postdoctoral Mentor Award, NIH
2012 & 2013 Fellows’ Award for Research Excellence, NIH

Member of:
American Society for Pharmacology and Experimental Therapeutics https://www.aspet.org/
Pharmacology Society (Councilor) https://www.aspet.org/MAPS/
Philadelphia Chapter of the Society for Neuroscience http://pcsfn.com/

Education/Academic qualification

Doctor of Philosophy, doctorate

Fingerprint Dive into the research topics where Thomas Keck is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Rowan University Application for 2019 Jean Dreyfus Lectureship for Undergraduate Institutions

Keck, T.

The Camille & Henry Dreyfus Foundation, Inc.

9/1/19 → 8/31/20

Project: Other project

Analgesia without Addiction: Synthesis and Development of Highly Selective Novel Analgesics

Keck, T.

New Jersey Health Foundation, Inc.

2/15/19 → 2/27/20

Project: Other project

Abuse liability and anti-addiction potential of the atypical mu opioid receptor agonist IBNtxA

Keck, T.

National Institutes of Health

4/1/17 → 3/31/19

Project: Research project

Research Output

  • 425 Citations
  • 14 h-Index
  • 22 Article
  • 1 Chapter

Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist

Moritz, A. E., Free, R. B., Weiner, W. S., Akano, E. O., Gandhi, D., Abramyan, A., Keck, T. M., Ferrer, M., Hu, X., Southall, N., Steiner, J., Aubé, J., Shi, L., Frankowski, K. J. & Sibley, D. R., May 28 2020, In : Journal of Medicinal Chemistry. 63, 10, p. 5526-5567 42 p.

Research output: Contribution to journal › Article

    • Neurochemical and behavioral comparisons of contingent and non-contingent methamphetamine exposure following binge or yoked long-access self-administration paradigms

    Schweppe, C. A., Burzynski, C., Jayanthi, S., Ladenheim, B., Cadet, J. L., Gardner, E. L., Xi, Z. X., van Praag, H., Newman, A. H. & Keck, T. M., Jul 1 2020, In : Psychopharmacology. 237, 7, p. 1989-2005 17 p.

    Research output: Contribution to journal › Article

    • Cognitive and behavioral effects of brief seizures in mice

    Batterman, A. I., DeChiara, J., Islam, A., Brenner, M. B., Fischer, B. D., Buono, R. J., Keck, T. & Ferraro, T., Sep 1 2019, In : Epilepsy and Behavior. 98, p. 249-257 9 p.

    Research output: Contribution to journal › Article

    • Dopamine D4 Receptor-Selective Compounds Reveal Structure-Activity Relationships that Engender Agonist Efficacy

    Keck, T. M., Free, R. B., Day, M. M., Brown, S. L., Maddaluna, M. S., Fountain, G., Cooper, C., Fallon, B., Holmes, M., Stang, C. T., Burkhardt, R., Bonifazi, A., Ellenberger, M. P., Newman, A. H., Sibley, D. R., Wu, C. & Boateng, C. A., Apr 11 2019, In : Journal of Medicinal Chemistry. 62, 7, p. 3722-3740 19 p.

    Research output: Contribution to journal › Article

    Open Access
    • 5 Scopus citations

    Multitarget 1,4-Dioxane Compounds Combining Favorable D2-like and 5-HT1A Receptor Interactions with Potential for the Treatment of Parkinson's Disease or Schizophrenia

    Del Bello, F., Ambrosini, D., Bonifazi, A., Newman, A. H., Keck, T. M., Giannella, M., Giorgioni, G., Piergentili, A., Cappellacci, L., Cilia, A., Franchini, S. & Quaglia, W., May 15 2019, In : ACS chemical neuroscience. 10, 5, p. 2222-2228 7 p.

    Research output: Contribution to journal › Article

    • 4 Scopus citations